Sugi Predict

Sugi Predict / Targets / GRN

GRN

Progranulin (PGRN) (Acrogranin) (Epithelin pr · P28799 · GRN on Sugi Atlas →

10,596 patent compounds predicted against GRN, 4,667 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2311794 SCHEMBL2311794 0.66 9/20
SCHEMBL1133872 SCHEMBL1133872 0.59 9/20
SCHEMBL574145 SCHEMBL574145 0.64 8/20
SCHEMBL1829148 SCHEMBL1829148 0.60 8/20
SCHEMBL1572486 SCHEMBL1572486 1.00 6/20
SCHEMBL1531745 SCHEMBL1531745 0.65 6/20
SCHEMBL1531749 SCHEMBL1531749 0.65 6/20
SCHEMBL2030609 SCHEMBL2030609 0.59 6/20
SCHEMBL2078660 SCHEMBL2078660 0.54 6/20
SCHEMBL1326795 SCHEMBL1326795 0.44 6/20
SCHEMBL1655474 SCHEMBL1655474 0.43 6/20
SCHEMBL893061 SCHEMBL893061 0.82 5/20
SCHEMBL1897360 SCHEMBL1897360 0.80 5/20
SCHEMBL350765 SCHEMBL350765 0.71 5/20
SCHEMBL352072 SCHEMBL352072 0.71 5/20
SCHEMBL350610 SCHEMBL350610 0.67 5/20
SCHEMBL352154 SCHEMBL352154 0.67 5/20
SCHEMBL2355530 SCHEMBL2355530 0.67 5/20
SCHEMBL2455065 SCHEMBL2455065 0.64 5/20
SCHEMBL2362846 SCHEMBL2362846 0.61 5/20

Clinical trials — most relevant to GRN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy PHASE2/PHASE3COMPLETED
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 PHASE3RECRUITING
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) PHASE2COMPLETED
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) PHASE2COMPLETED
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) PHASE1/PHASE2RECRUITING
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) PHASE2COMPLETED
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation PHASE1COMPLETED
Safety Study of TPI-287 to Treat CBS and PSP PHASE1COMPLETED
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations PHASE1COMPLETED
Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 PHASE1COMPLETED
[18F]ACI-19626 PET in TDP-43 Proteinopathies EARLY_PHASE1RECRUITING
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers nanCOMPLETED
Neurofilament Surveillance Project (NSP) nanACTIVE_NOT_RECRUITING
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) nanCOMPLETED
Predict to Prevent PGRN Disease nanWITHDRAWN
Central and Systemic Inflammation in Alzheimer's Disease nanCOMPLETED
Genetic Frontotemporal Dementia Initiative for Neurodevelopment nanRECRUITING
GENetic Fronto Temporal Dementia Initiative in Lille nanRECRUITING
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects nanCOMPLETED
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects nanCOMPLETED
Characterisation of Primary Progressives Aphasias nanUNKNOWN
ADDIA Proof-of-Performance Clinical Study nanCOMPLETED
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
Neuroinflammation in FTLD nanACTIVE_NOT_RECRUITING
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum nanNOT_YET_RECRUITING
Genomic Translation for Amyotrophic Lateral Sclerosis Care nanCOMPLETED
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRN binder may also engage these)

ProteinNameSimilarity
P28797 — 1.000 P28797 →
P23785 — 0.992 P23785 →
P28798 — 0.991 P28798 →
Q9EPX2 — 0.979 Q9EPX2 →
Q8R0S6 — 0.977 Q8R0S6 →
Q61483 — 0.977 Q61483 →
Q9R097 — 0.977 Q9R097 →
Q9NR61 — 0.977 Q9NR61 →
O95428 — 0.977 O95428 →
Q80YC5 — 0.977 Q80YC5 →
Q08E66 — 0.976 Q08E66 →
Q8TEU8 — 0.976 Q8TEU8 →
D3ZTE0 — 0.976 D3ZTE0 →
Q7TQH7 — 0.976 Q7TQH7 →
O43278 — 0.976 O43278 →
Q9ET61 — 0.975 Q9ET61 →
O00548 — 0.975 O00548 →
Q14112 — 0.975 Q14112 →
DNER Delta and Notch-like epidermal growth factor-related receptor 0.974 landscape →
P0DN43 — 0.974 P0DN43 →
P15306 — 0.974 P15306 →
P0C5J5 — 0.974 P0C5J5 →
Q9NPY3 — 0.974 Q9NPY3 →
Q05793 — 0.974 Q05793 →
B2BS84 — 0.974 B2BS84 →
Q9R098 — 0.974 Q9R098 →
O97507 — 0.974 O97507 →
Q3U515 — 0.974 Q3U515 →
Q8IVN8 — 0.973 Q8IVN8 →
Q7TQN3 — 0.973 Q7TQN3 →